Navigation Links
Skinvisible to Present at Merriman Curhan Ford & Co.'s Investor Summit 2007
Date:9/10/2007

Hundreds of Institutional Investors to Attend Conference

LAS VEGAS, Sept. 10 /PRNewswire-FirstCall/ -- Skinvisible, Inc. (OTC Bulletin Board: SKVI / Website: http://www.skinvisible.com), the developers of Invisicare(R), a proprietary polymer delivery system for topically applied dermatology products, today announced that Mr. Terry Howlett, President & CEO, will present at the 4th annual Merriman Curhan Ford & Co. Investor Summit on September 18, 2007 at 2:15 PM. This event will be held at the Mark Hopkins InterContinental Hotel in San Francisco.

(Logo: http://www.newscom.com/cgi-bin/prnh/20030416/LAW068LOGO)

(Logo: http://www.newscom.com/cgi-bin/prnh/20040503/INVISICARELOGO)

More information about the conference can be found at: http://www.merrimanco.com

About Merriman Curhan Ford & Co.

Merriman Curhan Ford & Co., a subsidiary of MCF Corporation (Amex: MEM), is an investment bank and securities broker-dealer focused on fast-growing companies and growth-oriented institutional investors. It provides investment research, brokerage and trading services primarily to institutions, as well as advisory and investment banking services to corporate clients. Its mission is to become a leader in the researching, advising, financing and trading of fast-growing companies. Merriman Curhan Ford & Co. is registered with the Securities and Exchange Commission as a broker-dealer and is a member of the National Association of Securities Dealers, Inc. and SIPC.

About Skinvisible Pharmaceuticals, Inc.

Skinvisible Pharmaceuticals, a wholly owned subsidiary of Skinvisible Inc., is a research-and-development company whose primary business objective is to license its proprietary formulations with Invisicare to pharmaceutical and cosmeceutical companies as well as assisting companies in revitalizing or enhancing their existing skin care products. Skinvisible receives a combination of research and development fees, upfront license fees, and ongoing royalties for the life of the patent. http://www.skinvisible.com

About Invisicare(R)

Invisicare is a patented polymer delivery system developed to hold active ingredients topically on the skin for extended periods of time. A key benefit is that Invisicare is non-occlusive on the skin, allowing normal skin respiration and perspiration. The Company has developed a portfolio of topical products using Invisicare for the dermatology and cosmeceutical industries. http://www.invisicare.com

Forward-Looking Statements

This press release contains 'forward looking' statements within the meaning of Section 21A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, and are subject to the safe harbors created thereby. Such statements involve certain risks and uncertainties associated with an emerging company. Actual results could differ materially from those projected in the forward looking statements as a result of risk factors discussed in Skinvisible, Inc. reports on file with the U.S. Securities and Exchange Commission (including, but not limited to, a report on Form 10Q for the quarter ending June 30, 2007)

Corporate Contact:

Terry Howlett, President/CEO

Skinvisible Pharmaceuticals, Inc

Phone: 702-433-7154

Email: info@skinvisible.com


'/>"/>
SOURCE Skinvisible, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Related medicine news :

1. Surgeons Presented Guidelines For Postoperative Atrial Fibrillation
2. Researchers Present Ways To Reduce The Risk Of Dementia
3. Researchers Present Data Regarding The Efficiency Of Herbs
4. Critically Ill Patients More At Risk Of Infection If Glucose Is Present In Their Lung Secretions
5. Ovarian Cancer Presents ‘Target Symptoms’ Six Months Before Diagnosi
6. Drug Reactions First Present Themselves In The Mouth
7. Reminiscing Into The Past Makes You Dissatisfied With The Present
8. Living In The Past Indicates Dissatisfaction With Present
9. Movies Represent Coma In A Wrong Way
10. Onchocerciasis: Presentation And Treatment
11. Researchers Warn That Routine Physical Examination Could Miss Breech Presentation
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/20/2017)... ... , ... Source Vitál Apothecary, a skin and body care company dedicated to ... had a successful visit to the 2017 ECRM Diet, Vitamin & Sports Nutrition Conference ... the nutritional, sports and health industries a chance to meet in private sessions with ...
(Date:1/20/2017)... ... January 20, 2017 , ... Bionic Sports Nutrition LLC, an ... life, announced it had a successful January ECRM Trade Show in Hilton Head, SC. ... States, which allows it to provide its products to all clients at reasonable prices. ...
(Date:1/20/2017)... ... January 20, 2017 , ... ATP Science, ... everyday lives, recently attended the January ECRM Trade Show in Hilton Head, SC, ... for its large range of supplements that keep the body functioning at its ...
(Date:1/20/2017)... (PRWEB) , ... January 20, 2017 , ... Michael and ... Dana Farber Cancer Institute. For Betsy, the clinical trial has been life-saving as ... has not worsened. , Betsy Brauser was diagnosed with ovarian cancer in 2009. ...
(Date:1/20/2017)... New York, NY (PRWEB) , ... January 20, ... ... drinks – VW+ 001 and its sugar-free alternative VW+ 002. The drinks have ... the body with optimal conditions to perform during your workout. , After a ...
Breaking Medicine News(10 mins):
(Date:1/19/2017)... , Jan. 19, 2017 Report Details ... ... Opportunities for Leading Companies – our new study reveals ... discusses issues and events affecting the Alzheimer,s disease therapeutics ... to answer these key questions: - How is the ...
(Date:1/19/2017)... 2017 Many patients don,t realize that they ... a pharmacy just a few blocks away charges only ... problem Medicationdiscountcard.com has created a price comparison ... much their medication will cost at most nearby pharmacies. ... Medicationdiscountcard.com takes all of the ...
(Date:1/19/2017)... , January 19, 2017 Incretin Mimetics/GLP-1 Agonists, ... Others The global anti-obesity drugs market is ... half of the forecast period and CAGR of 38.7% in the ... grow at a CAGR of 32.8% from 2016 to 2027. The ... 2021, and $24,063 million in 2027. ...
Breaking Medicine Technology: